https://www.businesswire.com/news/home/20260413512111/en/Ifinatamab-Deruxtecan-Granted-Priority-Review-in-the-U.S.-for-Adult-Patients-with-Previously-Treated-Extensive-Stage-Small-Cell-Lung-Cancer-who-Experienced-Disease-Progression-on-or-After-Platinum-Based-Chemotherapy
Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously...
I-DXd BLA Acceptance
https://experts.umn.edu/en/projects/a-phase-1b2-multicenter-open-label-study-of-ifinatamab-deruxtecan/
A Phase 1B/2, Multicenter, Open-label Study of Ifinatamab Deruxtecan (I-DXd), A B7- H3...